Abstract
There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a significant coagulopathy, a phenomenon termed "COVID-19 associated coagulopathy." COVID-19 has been associated with increased rates of both venous and arterial thromboembolic events, a source of significant morbidity and mortality in this disease. Further evidence suggests a link between the inflammatory response and coagulopathy associated with COVID-19. This presents a unique set of challenges for diagnosis, prevention, and treatment of thrombotic complications. In this review, we summarize and discuss the current literature on laboratory coagulation disruptions associated with COVID-19 and the clinical effects of thromboembolic events including pulmonary embolism, deep vein thrombosis, peripheral arterial thrombosis, and acute ischemic stroke in COVID-19. Endothelial injury and augmented innate immune response are implicated in the development of diffuse macro- and microvascular thrombosis in COVID-19. The pathophysiology of COVID-19 associated coagulopathy is an important determinant of appropriate treatment and monitoring of these complications. We highlight the importance of diagnosis and management of dysregulated coagulation in COVID-19 to improve outcomes in COVID-19 patients with thromboembolic complications.
Original language | English (US) |
---|---|
Pages (from-to) | 700-716 |
Number of pages | 17 |
Journal | Shock |
Volume | 55 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2021 |
Keywords
- COVID-19
- Coagulation
- DVT
- coagulopathy
- pulmonary embolism
- thromboembolism
- thrombosis
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
- Emergency Medicine